Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
AC Immune SA (ACIU) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/22/2023 144 Form 144 - Report of proposed sale of securities:
08/21/2023 144 Form 144 - Report of proposed sale of securities:
08/17/2023 144 Form 144 - Report of proposed sale of securities:
08/09/2023 144 Form 144 - Report of proposed sale of securities:
08/08/2023 144 Form 144 - Report of proposed sale of securities:
08/04/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "​",
"​",
"​",
"​"
07/26/2023 6-K Quarterly results
07/24/2023 144 Form 144 - Report of proposed sale of securities:
07/21/2023 144 Form 144 - Report of proposed sale of securities:
07/18/2023 144 Form 144 - Report of proposed sale of securities:
07/13/2023 144 Form 144 - Report of proposed sale of securities:
07/12/2023 144 Form 144 - Report of proposed sale of securities:
07/10/2023 144 Form 144 - Report of proposed sale of securities:
07/07/2023 144 Form 144 - Report of proposed sale of securities:
07/03/2023 144 Form 144 - Report of proposed sale of securities:
06/30/2023 144 Form 144 - Report of proposed sale of securities:
06/30/2023 144 Form 144 - Report of proposed sale of securities:
05/24/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Invitation to the Annual General Meeting 2023 To the Shareholders of AC Immune SA",
"Consolidated Financial Statements (IFRS) as at and for the years ended December 31, 2022, 2021 and 2020 (incorporated by reference to Item 18 of Part III of AC Immune’ s Annual Report on Form 20-F for the fiscal year ended December 31, 2022 filed on March 16, 2023)"
04/28/2023 6-K Quarterly results
Docs: "6-K",
"Interim Condensed Consolidated Financial Statements (Unaudited) (IFRS) as of and for the three months ended March 31, 2023",
"Management’s Discussion and Analysis of Financial Condition and Results of Operations",
"AC Immune Reports First Quarter 2023 Financial Results",
"AC Immune SA"
03/16/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update",
"2022 Annual Report"
03/16/2023 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
03/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K"
02/14/2023 SC 13G/A AFFiRiS AG reports a 12% stake in AC IMMUNE SA
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/27/2023 SC 13G/A ELI LILLY & Co reports a 4.3% stake in * AC Immune SA
01/26/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"AC Immune’ s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’ s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial"
11/30/2022 6-K Quarterly results
10/28/2022 6-K Quarterly results
09/26/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"AC Immune Partner LMI Progresses Tau PET Tracer PI-2620 into Late-stage Development in Alzheimer’ s Disease"
08/02/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Detailed data from the phase II Crenezumab Alzheimer’ s Prevention Initiative Study in Autosomal Dominant Alzheimer’ s Disease Presented at AAIC"
07/28/2022 6-K Quarterly results
06/24/2022 6-K Quarterly results
06/16/2022 6-K Quarterly results
05/25/2022 6-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy